Diagnosis and treatment of cystic lung disease

Park, Sanghoon

doi:10.3904/kjim.2016.242

Cited by 27 publications

(39 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The disorders and processes associated with the new biomarkers identified in this study provide clinical tools for the evaluation and treatment of SARS-CoV-2 infection and disease symptomatology and progression ( Figure 7 ). For example, detection of high HNF3A levels in nonsevere or severe patients suggests their diagnosis and treatment to reduce airway dilatation with production of large cysts associated with function of airway epithelial cells ( 96 ).…”

Section: Discussionmentioning

confidence: 99%

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic caused by SARS-CoV-2 challenges the understanding of factors affecting disease progression and severity. The identification of prognostic biomarkers and physiological processes associated with disease symptoms is relevant for the development of new diagnostic and therapeutic interventions to contribute to the control of this pandemic. To address this challenge, in this study, we used a quantitative proteomics together with multiple data analysis algorithms to characterize serum protein profiles in five cohorts from healthy to SARS-CoV-2-infected recovered (hospital discharge), nonsevere (hospitalized), and severe [at the intensive care unit (ICU)] cases with increasing systemic inflammation in comparison with healthy individuals sampled prior to the COVID-19 pandemic. The results showed significantly dysregulated proteins and associated biological processes and disorders associated to COVID-19. These results corroborated previous findings in COVID-19 studies and highlighted how the representation of dysregulated serum proteins and associated BPs increases with COVID-19 disease symptomatology from asymptomatic to severe cases. The analysis was then focused on novel disease processes and biomarkers that were correlated with disease symptomatology. To contribute to translational medicine, results corroborated the predictive value of selected immune-related biomarkers for disease recovery [Selenoprotein P (SELENOP) and Serum paraoxonase/arylesterase 1 (PON1)], severity [Carboxypeptidase B2 (CBP2)], and symptomatology [Pregnancy zone protein (PZP)] using protein-specific ELISA tests. Our results contributed to the characterization of SARS-CoV-2–host molecular interactions with potential contributions to the monitoring and control of this pandemic by using immune-related biomarkers associated with disease symptomatology.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pneumothorax developed in 66.7% and 75% was recurrent. However, LAM, pulmonary Langerhans cell histiocytosis, lymphocytic interstitial pneumonia/follicular bronchiolitis, and amyloidosis should be considered in patients with multiple lung cysts [5].…”

Section: Discussionmentioning

confidence: 99%

Anesthetic Management in Birt-Hogg-Dubé Syndrome with Spontaneous and Recurrent Pneumothorax during Recovery after Laparoscopic-Assisted Partial Nephrectomy

Lee

2019

ACC

View full text Add to dashboard Cite

Birt-Hogg-Dubé Syndrome (BHDS) is an inherited autosomal dominant disorder associated with 3 clinical manifestations, including skin fibrofolliculomas, multiple lung cysts and kidney tumors. These symptoms generally do not appear till adult. BHDS can be suggested by clinical manifestations but is definitively confirmed by molecular genetic testing to detect mutations in the FLCN gene [1][2][3][4].The pulmonary manifestations of BHDS are common findings and mainly related to multiple lung cysts and development of spontaneous pneumothorax. In the rate of occurrence of pneumothorax, patients

show abstract

“…Las enfermedades pulmonares quísticas (EPQ) pueden ser asintomáticas, pero la disnea progresiva, tos y opresión torácica son frecuentes [2]. La EPQ incluye una constelación de trastornos pulmonares que se originan por diversas causas, pero que tienen en común una deformidad quística anatómica [3].…”

Section: Introductionunclassified

Enfermedad Pulmonar Quística Idiopática

Herwig

Palma

Torres

et al. 2021

Rev. méd. (Col. Méd. Cir. Guatem.)

View full text Add to dashboard Cite

Las Enfermedades Pulmonares Quísticas incluyen un grupo heterogéneo de patologías con múltiples causas. La presentación clínica es variable y generalmente incluye disnea progresiva, tos y opresión torácica. El diagnóstico suele ser difícil. La tomografía torácica de alta resolución juega un rol esencial. El tratamiento depende de la causa primaria, sin embargo, en algunos casos, ésta no se puede determinar. Presentamos el caso de una mujer de 45 años con enfermedad pulmonar quística idiopática.

show abstract

Diagnosis and treatment of cystic lung disease

Cited by 27 publications

References 59 publications

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

Anesthetic Management in Birt-Hogg-Dubé Syndrome with Spontaneous and Recurrent Pneumothorax during Recovery after Laparoscopic-Assisted Partial Nephrectomy

Enfermedad Pulmonar Quística Idiopática

Contact Info

Product

Resources

About